Möricke et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477-4489.-Reference-Cited by-同舟云学术

Möricke et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477-4489.

Published:2009-04-30 Issue:18 Volume:113 Page:4478-4478
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/113/18/4478/1457067/zh801809004478.pdf

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating the chemotherapy-induced acute motor and sensory axonal neuropathy and diabetic ketoacidosis in an adolescent girl with acute lymphoblastic leukemia: A case report;Pediatric Companion;2023-05

2. The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin‐Frankfurt‐Münster (BFM)95‐based protocol;British Journal of Haematology;2021-12-08

3. Treatment of childhood acute lymphoblastic leukemia in Iraq: a 17-year experience from a single center;Leukemia & Lymphoma;2021-08-06

4. “SOCIOECONOMIC FACTORS AFFECTING SURVIVAL IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA FROM NORTH-EAST INDIA”;INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH;2020-10-01

5. Diagnosing neuroleukemiosis: Is there a role for 18 F-FDG-PET/CT?;Revista Española de Medicina Nuclear e Imagen Molecular;2017-11